Around 55,900 new cases of breast cancer are diagnosed in the UK yearly. Almost nine in ten women with breast cancer in England and Wales survive for at least five years; however, around 1,000 UK women still die of breast cancer every month. Our research is aiming to increase the survival rate through: Collaboration: connecting researchers with an interest in Breast Cancer and their expertise across Cambridge; Personalising breast cancer treatment: understanding individual breast cancers and how they respond to different treatments; Novel Clinical trial designs: Time and cost efficient ways to test new treatments and rapid translation between clinic and lab.
We are a team of experts in laboratory, translational and clinical research who collaborate to achieve an ambitious aim – to provide personalised, precision treatments for people with breast cancer.
The overarching vision of the Breast Programme is to develop an integrated clinical-translational platform bridging basic science to clinical impact that improves survival for all sub-types of breast cancer whilst de-escalating treatment appropriately to avoid unnecessary toxicity. The Breast Programme prioritises answering critical clinical questions by understanding the biology underlying interconnecting networks that drive the different breast cancer sub-types and the different transition states of breast cancer.
The Vision for the Breast Programme has been driven by the questions that matter to our patients:
• Can my cancer be cured / what is the chance I might die?
• What is the best treatment option for me and why?
• How early will I know if my treatment is working?
• Are my family also at risk?
• What are the potential side-effects?
• Do I need more treatment or closer follow-up?
• How will I know if my disease is returning?
The long term aim of the Breast Cancer Virtual Institute is to deliver precision breast cancer care locally, regionally and nationally using the new Precision Breast Cancer Institute as the foundation for a new treatment paradigm that can be deployed nationally and potentially internationally.
A major research project analysing the genetic barcodes of 2,000 breast cancer samples has identified 10 different types of breast cancer. Each has a different survival rate and requires a different course of treatment. The results of this research are being used to develop new tests to diagnose different breast cancer types, which will then enable each patient to be given the most effective course of treatment. Cambridge is also helping to unravel the full genetic sequence for breast cancer, as part of an international initiative to identify the genetic blueprint of 50 cancers.
The Cambridge Breast Cancer Research Unit has collected over 20,000 tumour samples from breast cancer patients. This large diverse collection of tissue samples will be essential in the development and testing of new ways to diagnose the different types of breast cancer.
Cambridge has established a ‘one-stop’ clinic, the Cambridge Breast Unit, for rapid diagnosis of breast cancer. The diagnostic accuracy of the triple assessment (clinical examination, imaging and biopsy) is 99.6%. Nine-year survival rates of breast cancer patients treated at Addenbrookes Hospital is 84%, compared with a regional average of 78%. Around half of patients diagnosed with breast cancer at the clinic enter a clinical trial run by the Cambridge Breast Cancer Research Unit. Find out more about the Cambridge Breast Unit.
Researchers in Cambridge have identified how the oestrogen receptor-cistrome in primary tumours modulates response to hormone therapy. They demonstrated differential oestrogen receptor (ER) binding events in primary breast cancer (a first ever) and revealed a role for the pioneer factor FoxA1 as a crucial ER regulatory protein in drug resistant contexts, providing the impetus to develop therapeutic FoxA1 inhibitors.
Repeat biopsies to study genomic evolution as a result of therapy are difficult, invasive and may be confounded by intra-tumour heterogeneity. We have demonstrated the clear advantages of using circulating tumour DNA (ctDNA) over other tests as a biomarker for monitoring treatment response and disease progression in patients with metastatic disease. Specifically, we have developed a new approach, sequencing of cancer exomes in plasma, to study a series of patients who have developed resistance to chemotherapy, hormone therapy and Trastuzumab, with the aim of identifying potential causing mutations.
Breast Cancer Programme Newsletter
The first edition of the new Breast Cancer Programme Newsletter was circulated to members on the 11th October 2021. If you would like to receive the newsletter in future you can request membership here: https://crukcambridgecentre.org.uk/login
Visiting Professor (on hold)
The CRUK Cambridge Centre Breast Cancer Programme hosts an annual visit for a Visiting Professor in September.
Breast Cancer Programme Research Day
We aim to hold a Breast Cancer Programme event early in 2022. Further details will be posted when available.